Compare ELLO & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ELLO | FATE |
|---|---|---|
| Founded | 1987 | 2007 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.4M | 260.0M |
| IPO Year | 1998 | 2013 |
| Metric | ELLO | FATE |
|---|---|---|
| Price | $17.91 | $1.02 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $5.72 |
| AVG Volume (30 Days) | 2.1K | ★ 1.5M |
| Earning Date | 12-01-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.88 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,646,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.00 | $0.95 |
| 52 Week High | $30.34 | $3.23 |
| Indicator | ELLO | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 41.27 | 19.93 |
| Support Level | $17.54 | N/A |
| Resistance Level | $20.40 | $1.38 |
| Average True Range (ATR) | 0.60 | 0.16 |
| MACD | -0.27 | -0.09 |
| Stochastic Oscillator | 14.92 | 1.75 |
Ellomay Capital Ltd is a renewable energy company. It develops and operates renewable energy projects in Europe, the USA, and Israel, employing diverse technologies such as solar power, natural gas, pumped hydro, and waste-to-energy solutions. Geographically, the company operates in segments: Italy; Spain; USA; Netherland and Israel. It derives maximum revenue from Spain.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.